Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).

@article{Pengo2011QuestionsAA,
  title={Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).},
  author={Vittorio Pengo and Luciano Crippa and Anna Falanga and Guido Finazzi and Francesco Marongiu and Gualtiero Palareti and Daniela Poli and Sophie Testa and Eros Tiraferri and Alberto Tosetto and Armando Tripodi and Cesare Manotti},
  journal={Thrombosis and haemostasis},
  year={2011},
  volume={106 5},
  pages={868-76}
}
Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

Similar Papers

Loading similar papers…